Back to results
US 2018/0008582 A1Published application
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AssigneeGlaxo Group Limited
InventorsDarrell BAKER, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
Life of this patent
Estimating the term…
Abstract
Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Claims68
A pharmaceutical combination product comprising
- a) a compound of the formula:
- wherein
- X− is a pharmaceutically acceptable anion;
- and
- b) a compound of the formula:
- or a pharmaceutically acceptable salt thereof (Compound (II)).
3 more elements
A dry powder inhaler comprising two compositions presented separately, wherein the first composition comprises
- i. 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide, and
- ii. lactose, and
- iii. magnesium stearate at an amount of about 0.6% w/w based on the total weight of the first composition;
- and the second composition comprises
- iv. 4-{(1R)-2-[(6-{2-[(2,6-dicholorobenzyl)oxy]ethoxy}hexyl)amino]1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, and
- v. lactose, and
- vi. magnesium stearate at an amount of about 1.0% w/w based on the total weight of the second composition.
4 more elements
Dependencies are inferred from the claim text.